Tag: drugs

New Report: At 7.0% CAGR, 3D Printed Drugs Market Size, Growth Analysis to accrue USD 437.04 million by 2025

The MarketWatch News Department was not involved in the creation of this content.

Sep 15, 2020 (Heraldkeepers) —
3D Printed Drugs market is valued at USD 272.17 million in 2018 and expected to reach USD 437.04 million by 2025 with a CAGR of 7.0% over the forecast period.

Key Players –

Some major key players for global 3D Printed Drugs market are 3D Printer Drug Machine, Aprecia Pharmaceuticals, Hewlett Packard Caribe, BV, LLC, GlaxoSmithKline Plc., FabRx Ltd., Cycle Pharmaceuticals and others.

Get Sample of This Report@https://brandessenceresearch.com/requestSample/PostId/432

Market Analysis of 3D Printed Drugs –

3D printed drugs are medications, which are designed by 3D printing technique to modify for individuals in a safe and effective way. 3D printed drugs are developed by using powder-liquid three dimensional printing technologies. This technique uses an aqueous fluid which is able to bind different or similar layer of powders and produces multiple types of

Read More

Multiple Sclerosis Drugs Market 2020 Global Industry Growth, Size, Share, Emerging Technology Trends, Regional Analysis and Challenges

The MarketWatch News Department was not involved in the creation of this content.

Sep 11, 2020 (The Expresswire) —
The global “multiple sclerosis drugs market” is expected to gain from the development of economical therapy to treat multiple sclerosis (MS), finds Fortune Business Insights in a report, titled “MULTIPLE SCLEROSIS DRUGS: GLOBAL MARKET ANALYSIS, INSIGHTS AND FORECAST, 2019-2026.” According to the report, the global market was worth US$ 23,460.3 Mn in 2018. The market is anticipated to expand at a CAGR of 6.7% and reach US$ 39,289.5 Mn by the end of 2026. The report offers a comprehensive overview of the global multiple sclerosis drugs market. The research report gives an entire study of the Multiple Sclerosis Drugs Market leaders with key statistics like sales, revenue, price, product picture and specifications, contact information, cost, capacity, production and company profile. The report offers critical information at the state of the enterprise.

Read More

New screening technology works to better predict drug’s shelf life and stability

pharmaceuticals
Credit: Pixabay/CC0 Public Domain

Biopharmaceuticals are a fast-growing sector of the pharmaceutical market, but these protein-based drugs can take many years to bring to market and cost more than $2 billion to develop. A large portion of that time and money is spent attempting to predict which drug from a vast library of candidates is the most stable and will have the longest shelf life. TemperSure, a new drug screening technology from Penn State startup GradienT°, aims to reduce both the time and financial costs in biological drug development by increasing certainty in drug shelf life and expiration dates.

“The challenge for drug developers is that they need to ‘place their bet’ on which drug candidate to further develop, and the costs associated with getting it wrong are significant,” said Dustin Ritter, Penn State technology licensing officer and GradienT°’s industry mentor. “TemperSure’s value lies in its ability to quickly predict

Read More